噻托溴铵奥达特罗能倍乐多少钱

Tiotropium bromide and olodaterol are a specific and selective anticholinergic drug. It is mainly used clinically for the treatment of chronic obstructive pulmonary disease (COPD). The recommended dose is once a day, with two sprays each time. The effect of Respimat lasts for 24 hours, and patients are advised not to overdose. Tiotropium, olodaterol, and Respimat should be used at the same time every day, and, since COPD is a long-term disease, patients can use it every day, not just when they have breathing problems. 

How much does tiotropium bromide, olodaterol, and Respimat cost? It is understood that the current price of tiotropium bromide, olodaterol, and Respimat per box is around $170. The price may change due to various factors such as exchange rates. Patients can consult the Medical Partner Travel Overseas Medical Consulting Service Company for specific prices and purchase methods.

Tiotropium bromide, olodaterol, and Respimat are available in two dosage forms, one is tiotropium bromide powder inhalation, and the other is Respimatium bromide and tiotropium bromide spray, corresponding to different usage methods. Below we mainly understand how to use spray.

Tiotropium bromide, olodaterol, and Respimat are colorless and clear liquids, which are packed in plastic bottles covered with aluminum shells. When used, they are inserted into the sprayer, press the device, and the liquid medicine is sprayed out in the form of mist. For inhalation use only. The recommended dose for adults is to inhale once daily via the Respimat inhaler device, preferably at the same time each day, taking 2 puffs each time. Do not overdose. 

The elderly can use tiotropium bromide and olodaterol at the recommended dosage, but the safety and effectiveness of the drug in children are unknown, so its use is not recommended for patients under 18 years of age. Patients with moderate to severe renal insufficiency (creatinine clearance ≤50ml/minute) need to be closely monitored while using Respimat. 

Recommended related hot articles: /newsDetail/83849.html